These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 1348483

  • 1. Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline.
    Frans E, Dom R, Demedts M.
    Eur Respir J; 1992 Feb; 5(2):263-5. PubMed ID: 1348483
    [Abstract] [Full Text] [Related]

  • 2. Pleuropulmonary disease associated with dopamine agonist therapy.
    Bhatt MH, Keenan SP, Fleetham JA, Calne DB.
    Ann Neurol; 1991 Oct; 30(4):613-6. PubMed ID: 1686385
    [Abstract] [Full Text] [Related]

  • 3. Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease.
    McElvaney NG, Wilcox PG, Churg A, Fleetham JA.
    Arch Intern Med; 1988 Oct; 148(10):2231-6. PubMed ID: 3178380
    [Abstract] [Full Text] [Related]

  • 4. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease.
    Ling LH, Ahlskog JE, Munger TM, Limper AH, Oh JK.
    Mayo Clin Proc; 1999 Apr; 74(4):371-5. PubMed ID: 10221467
    [Abstract] [Full Text] [Related]

  • 5. Pleuropulmonary involvement during bromocriptine treatment.
    Kinnunen E, Viljanen A.
    Chest; 1988 Nov; 94(5):1034-6. PubMed ID: 3180854
    [Abstract] [Full Text] [Related]

  • 6. Overnight switching from ergot-derived dopamine agonists to pramipexole in patients with Parkinson's disease: an open preliminary trial in Japan.
    Ohno H, Nakajima M, Fujioka S, Iwamoto K, Kawamura M.
    J Clin Neurosci; 2009 Jun; 16(6):790-2. PubMed ID: 19286385
    [Abstract] [Full Text] [Related]

  • 7. [Pleural effusion and pulmonary hypertension in a patient with Parkinson disease treated with cabergoline].
    Haro-Estarriol M, Sabater-Talaverano G, Rodríguez-Jerez F, Obrador-Lagares A, Genís-Batlle D, Sendra-Salillas S.
    Arch Bronconeumol; 2009 Feb; 45(2):100-2. PubMed ID: 19232272
    [Abstract] [Full Text] [Related]

  • 8. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.
    Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF.
    N Engl J Med; 1994 Oct 06; 331(14):904-9. PubMed ID: 7915824
    [Abstract] [Full Text] [Related]

  • 9. [Early pleuropulmonary toxicity associated with cabergoline, an antiparkinsonian drug].
    Villavicencio C, Ramírez-Sarmiento A, Gayete A, Grau S, Orozco-Levi M.
    Arch Bronconeumol; 2007 Sep 06; 43(9):519-22. PubMed ID: 17919420
    [Abstract] [Full Text] [Related]

  • 10. Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease.
    Inzelberg R, Nisipeanu P, Rabey MJ, Korczyn AD.
    Mov Disord; 1995 Sep 06; 10(5):604-7. PubMed ID: 8552112
    [Abstract] [Full Text] [Related]

  • 11. Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson's disease.
    Lancet; 1981 Jan 03; 1(8210):44-5. PubMed ID: 6109080
    [No Abstract] [Full Text] [Related]

  • 12. Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease.
    Townsend M, MacIver DH.
    Heart; 2004 Aug 03; 90(8):e47. PubMed ID: 15253989
    [Abstract] [Full Text] [Related]

  • 13. Cabergoline in Parkinson's disease complicated by motor fluctuations.
    Geminiani G, Fetoni V, Genitrini S, Giovannini P, Tamma F, Caraceni T.
    Mov Disord; 1996 Sep 03; 11(5):495-500. PubMed ID: 8866490
    [Abstract] [Full Text] [Related]

  • 14. [Pleural effusion induced by bromocriptine].
    Diot E, Diot P, Le Rolland A, Jonville AP, Lasfargues G, Lemarie E, Lavandier M, Guilmot JL.
    Rev Mal Respir; 1990 Sep 03; 7(2):175-7. PubMed ID: 2320790
    [Abstract] [Full Text] [Related]

  • 15. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
    Linazasoro G, Spanish Dopamine Agonists Study Group.
    Clin Neuropharmacol; 2008 Sep 03; 31(1):19-24. PubMed ID: 18303487
    [Abstract] [Full Text] [Related]

  • 16. [Two cases of patients with Parkinson's disease developing valvular heart disease while taking cabergoline].
    Sato T, Kikuchi A, Onoue N, Hiramoto T, Oumi M, Onodera J.
    Rinsho Shinkeigaku; 2008 Jul 03; 48(7):486-91. PubMed ID: 18717182
    [Abstract] [Full Text] [Related]

  • 17. [Bromocriptine-induced pleuropneumopathy].
    Schmid PA, Suter T, Speich R, Eberli F, Greminger P.
    Dtsch Med Wochenschr; 1994 Nov 11; 119(45):1543-6. PubMed ID: 7956789
    [Abstract] [Full Text] [Related]

  • 18. [Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine].
    Montastruc JL, Schmitt L, Bagheri H.
    Rev Neurol (Paris); 2003 Apr 11; 159(4):441-3. PubMed ID: 12773874
    [Abstract] [Full Text] [Related]

  • 19. Treatment of Parkinson's disease and restless legs syndrome with cabergoline, a long-acting dopamine agonist.
    Porter MC, Appiah-Kubf LS, Chaudhuri KR.
    Int J Clin Pract; 2002 Apr 11; 56(6):468-74. PubMed ID: 12166546
    [Abstract] [Full Text] [Related]

  • 20. Comparison between lergotrile and bromocriptine in parkinsonism.
    Teychenne PF, Pfeiffer RF, Bern SM, McInturff D, Calne DB.
    Ann Neurol; 1978 Apr 11; 3(4):319-24. PubMed ID: 666273
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.